Safety of NTR-101 for acute alcohol-related hepatitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests a new medicine called NTR-101 for people with severe liver inflammation caused by alcohol. It aims to see if the drug is safe and tolerable, and may offer a new treatment option for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a confirmed diagnosis of acute alcohol-related hepatitis (liver inflammation caused by drinking).
- Your body mass index (BMI) must be between 20 and 40 – this is a measure of weight relative to height.
- You must be willing to use reliable birth control if you or your partner could become pregnant.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.
- You must not have other causes of liver disease, active infections (including HIV), or be at high risk for alcohol withdrawal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a protein called alpha-1 antitrypsin can help people with severe liver inflammation caused by heavy drinking. It may reduce the damage and improve recovery.
This trial tests a combination of treatments for people with severe alcohol-related liver disease (alcoholic hepatitis) that has not responded to standard care. The goal is to improve liver function and help you stop drinking.
This trial tests a new medicine called MRG-001 for people with severe alcoholic hepatitis, a liver condition caused by heavy drinking. The study aims to see if the drug can help improve liver function and reduce symptoms.
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
This trial looks at the gut bacteria (microbiome) in people with severe alcoholic hepatitis to understand how it affects the illness. It may help doctors find better ways to treat this condition.
This early-phase study is testing a treatment approach for people with alcoholic hepatitis (liver inflammation caused by heavy alcohol use). It may help by improving liver function and outcomes in people who meet specific lab and health criteria.
Hear when a new Alcohol-Associated Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.